BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $88 from $90 but keeps an Outperform rating on the shares. The company expects to disclose pivotal data evaluating ...
Arvinas, Inc. is a clinical-stage biotech firm focusing on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. We believe Arvinas is a short due to weak ...
Piper Sandler raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps an Overweight rating on the shares. ARV-102 is an oral, CNS-penetrant LRRK2 degrader in development for ...
Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After this speaker’s ...
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...
The findings were presented in Chicago at the annual meeting of the American Society of Clinical Oncology and published in The New England Journal of Medicine. The trial found the experimental drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback